TNI BioTech, Inc. (TNIB) was formed in 2012 to acquire patents, develop treatments, market and license our immunotherapies for the treatment of cancer, HIV/AIDS and autoimmune diseases using methionine enkephalin (MENK) and low dose naltrexone (LDN). The first patents and therapies acquired were from Dr. Nicholas P. Plotnikoff and Dr. Fengping Shan.
For over twenty-five years, Dr. Plotnikoff has been credited with achieving major breakthroughs in the treatment of certain cancers and the treatment of HIV/AIDS. Dr. Plotnikoff with Dr. Bernard Bihari completed Phase 1 and early Phase 2 clinical trials in the United States using MENK, and he also collaborated with Dr. Joseph Wybran from Belgium on clinical trials for treatment by MENK for patients with HIV/AIDS. Beginning in 2007, trials continued in China with the support of China Medical University and Dr. Shan using MENK. TNI BioTech, Inc. is now partnering with Dr.. Shan on treating cancer patients with IRT-101 and IRT-102 in China, and these studies are showing very promising results.
Patents related to these studies were filed in China in 2009 and were approved in 2011. In the last year the results of studies involving the mechanism of action of MENK, have been published in a number of international journals. These studies include the findings that MENK stimulates interactions between dendritic cells and T cells, inhibits regulatory T cells. They also show MENK had higher potency than Interleukin -2 (IL-2) or Interferon-γ (IFN-γ), two widely known immunotherapeutic cytokines.